AlloVir (ALVR) Competitors $4.28 -0.27 (-5.93%) As of 09/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock ALVR vs. MEIP, STTK, CRVO, ALTS, ANEB, ENTX, KLRS, CRDL, OVID, and VXRTShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include MEI Pharma (MEIP), Shattuck Labs (STTK), CervoMed (CRVO), ALT5 Sigma (ALTS), Anebulo Pharmaceuticals (ANEB), Entera Bio (ENTX), Kalaris Therapeutics (KLRS), Cardiol Therapeutics (CRDL), Ovid Therapeutics (OVID), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Its Competitors MEI Pharma Shattuck Labs CervoMed ALT5 Sigma Anebulo Pharmaceuticals Entera Bio Kalaris Therapeutics Cardiol Therapeutics Ovid Therapeutics Vaxart AlloVir (NASDAQ:ALVR) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership. Does the media prefer ALVR or MEIP? In the previous week, MEI Pharma had 5 more articles in the media than AlloVir. MarketBeat recorded 5 mentions for MEI Pharma and 0 mentions for AlloVir. MEI Pharma's average media sentiment score of 0.19 beat AlloVir's score of 0.00 indicating that MEI Pharma is being referred to more favorably in the news media. Company Overall Sentiment AlloVir Neutral MEI Pharma Neutral Do insiders and institutionals hold more shares of ALVR or MEIP? 66.1% of AlloVir shares are owned by institutional investors. Comparatively, 52.4% of MEI Pharma shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 3.1% of MEI Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher earnings and valuation, ALVR or MEIP? MEI Pharma is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$20.23-0.21MEI PharmaN/AN/A$17.78M-$4.75-0.67 Which has more risk and volatility, ALVR or MEIP? AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Is ALVR or MEIP more profitable? AlloVir's return on equity of -71.03% beat MEI Pharma's return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -71.03% -61.27% MEI Pharma N/A -77.00%-64.79% SummaryAlloVir beats MEI Pharma on 6 of the 10 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.58M$287.07M$5.79B$10.15BDividend YieldN/AN/A5.69%4.60%P/E Ratio-0.21N/A74.5925.92Price / SalesN/A420.31453.5485.33Price / CashN/A22.4437.0859.91Price / Book0.1510.9112.156.29Net Income-$190.42M-$111.61M$3.28B$270.77M7 Day Performance-8.15%0.83%0.99%3.36%1 Month Performance60.30%5.52%7.21%6.41%1 Year Performance-75.16%-16.23%63.07%28.24% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$4.28-5.9%N/A-73.8%$21.58MN/A-0.21110High Trading VolumeMEIPMEI Pharma1.3232 of 5 stars$2.84-5.5%N/A+5.6%$92.93MN/A-0.60100Upcoming EarningsGap UpHigh Trading VolumeSTTKShattuck Labs3.9289 of 5 stars$1.94+3.1%$4.00+106.3%-46.9%$92.93M$5.72M-1.60100Positive NewsShort Interest ↓Analyst RevisionCRVOCervoMed3.8331 of 5 stars$9.94-0.6%$19.29+94.1%-41.4%$91.90M$9.74M-3.814Positive NewsAnalyst RevisionALTSALT5 Sigma0.2118 of 5 stars$4.17+0.8%N/A+71.1%$89.79M$22.26M0.00170Positive NewsShort Interest ↑ANEBAnebulo Pharmaceuticals2.461 of 5 stars$2.19-0.7%$5.50+151.7%+13.6%$89.76MN/A-8.404News CoveragePositive NewsGap UpENTXEntera Bio1.502 of 5 stars$1.95-2.8%$10.00+414.1%+3.4%$88.81M$180K-7.4820Positive NewsKLRSKalaris Therapeutics1.889 of 5 stars$4.69+1.1%$3.00-36.0%N/A$87.70MN/A0.00110News CoverageGap DownCRDLCardiol Therapeutics2.3299 of 5 stars$1.05-0.5%$8.00+665.6%-54.1%$87.48MN/A-3.0720Short Interest ↑OVIDOvid Therapeutics4.538 of 5 stars$1.25+0.4%$3.10+149.0%+11.6%$87.11M$570K-2.3160Positive NewsVXRTVaxart1.9172 of 5 stars$0.38-1.4%$2.00+427.0%-58.5%$86.88M$47.40M-1.41120Gap Down Related Companies and Tools Related Companies MEIP Alternatives STTK Alternatives CRVO Alternatives ALTS Alternatives ANEB Alternatives ENTX Alternatives KLRS Alternatives CRDL Alternatives OVID Alternatives VXRT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
